Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) is expected to issue its Q1 2025 quarterly earnings data before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $44.88 million for the quarter.
Akebia Therapeutics (NASDAQ:AKBA - Get Free Report) last posted its earnings results on Thursday, March 13th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.05). The business had revenue of $46.50 million during the quarter, compared to analysts' expectations of $37.36 million. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Akebia Therapeutics Stock Down 3.5 %
AKBA traded down $0.09 during trading on Monday, hitting $2.37. The company had a trading volume of 2,070,915 shares, compared to its average volume of 2,787,372. The firm's 50-day moving average price is $2.00 and its 200 day moving average price is $1.96. The company has a market capitalization of $619.12 million, a PE ratio of -10.28 and a beta of 0.87. Akebia Therapeutics has a one year low of $0.80 and a one year high of $2.89.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on AKBA. Piper Sandler lifted their price objective on shares of Akebia Therapeutics from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, March 14th. Leerink Partners assumed coverage on Akebia Therapeutics in a research note on Monday, April 28th. They set an "outperform" rating and a $7.00 target price for the company. Leerink Partnrs upgraded Akebia Therapeutics to a "strong-buy" rating in a research note on Monday, April 28th. StockNews.com upgraded shares of Akebia Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Jefferies Financial Group began coverage on shares of Akebia Therapeutics in a research note on Tuesday, April 1st. They set a "buy" rating and a $6.00 target price for the company. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus price target of $6.63.
Check Out Our Latest Stock Report on AKBA
Akebia Therapeutics Company Profile
(
Get Free Report)
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
See Also
Before you consider Akebia Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akebia Therapeutics wasn't on the list.
While Akebia Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
